PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28739774
OWN - NLM
STAT- MEDLINE
DA  - 20170725
DCOM- 20170803
LR  - 20170803
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 8
DP  - 2017 Aug
TI  - Study of Preoperative Antiviral Treatment of Patients with HCC Negative for
      HBV-DNA.
PG  - 4701-4706
AB  - AIM: To study preoperative HBV-DNA negative HBV-related hepatocellular carcinoma 
      (HCC) which was reactivated after surgery and could influence liver function and 
      HCC recurrence. PATIENTS AND METHODS: Patients were divided into two groups
      according to preoperative antiviral therapy status. The control group comprised
      of 102 preoperative HBV-DNA-negative patients who had not undergone antiviral
      therapy before surgery. In the treatment group, all HBV-DNA-negative patients
      (n=63) received entecavir 3-5 days before surgery and for 12 months after
      surgery. Patients were followed-up regularly, during the preoperative period, and
      at 1, 3, 6, 12, 18, 24, 30 and 36 months postoperatively. The data for the two
      groups were analyzed including the level of HBV-DNA and HBV-DNA activation; liver
      function; 1-, 2- and 3-year survival rate; cumulative survival time; and tumor
      recurrence. RESULTS: Liver function in the treatment group was better than that
      of the control group12 months after surgery. Compared to the control group, total
      bilirubin in the treatment group was significantly better at 6 and 12 months
      after surgery (p<0.05 and p<0.001, respectively). Serum albumin, alanine
      aminotransferase and prothrombin time in the treatment group was significantly
      better than that of controls 12 months after surgery (p<0.001). In the treatment 
      group, two cases (3.17%) had HBV-DNA activation while there were 13 cases
      (12.75%) with HBV-DNA activation in the control group (p<0.05). There were 51
      cases with tumor recurrence in the control group, that was statistically
      significantly higher than recurrent cases in the treatment group (p<0.05).
      Postoperative 1-, 2- and 3-year cumulative overall survival rates were 94.12%,
      81.37% and 52.94%, respectively, for the control group and 93.65%, 77.78% and
      71.43%, respectively, for the treatment group (p=0.006). There was no
      statistically significant difference in disease-free survival between the two
      groups (p=0.231). CONCLUSION: Antiviral treatment of HBV-related HCC with
      negative HBV-DNA is beneficial to liver function, coagulation function, disease
      control, prevention of tumor recurrence, improvement of patient quality of life, 
      reduces the death rate and prolongs survival duration.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Liu, Xiao-Fang
AU  - Liu XF
AD  - Department of Hepatobiliary Surgery, Affiliated Yantai Yuhuangding Hospital,
      Qingdao University Medical College, Yantai, P.R. China [email protected]
FAU - Zhang, Tong
AU  - Zhang T
AD  - Department of Hepatobiliary Surgery, Affiliated Yantai Yuhuangding Hospital,
      Qingdao University Medical College, Yantai, P.R. China.
FAU - Tang, Kun
AU  - Tang K
AD  - Department of Hepatobiliary Surgery, Affiliated Yantai Yuhuangding Hospital,
      Qingdao University Medical College, Yantai, P.R. China.
FAU - Sui, Lu-Lu
AU  - Sui LL
AD  - Department of Hepatobiliary Surgery, Affiliated Yantai Yuhuangding Hospital,
      Qingdao University Medical College, Yantai, P.R. China.
FAU - Xu, Gang
AU  - Xu G
AD  - Department of Hepatobiliary Surgery, Affiliated Yantai Yuhuangding Hospital,
      Qingdao University Medical College, Yantai, P.R. China.
FAU - Liu, Qiang
AU  - Liu Q
AD  - Department of Hepatobiliary Surgery, Affiliated Yantai Yuhuangding Hospital,
      Qingdao University Medical College, Yantai, P.R. China.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antiviral Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DNA, Viral)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antiviral Agents/*therapeutic use
MH  - Biomarkers, Tumor
MH  - Blood Coagulation
MH  - Carcinoma, Hepatocellular/diagnosis/*etiology/mortality/surgery
MH  - DNA, Viral/*blood
MH  - Female
MH  - Hepatitis B virus/*genetics
MH  - Hepatitis B, Chronic/complications/*drug therapy/*virology
MH  - Humans
MH  - Liver Function Tests
MH  - Liver Neoplasms/diagnosis/*etiology/mortality/surgery
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Preoperative Care
MH  - Recurrence
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Tumor Burden
MH  - Virus Activation
OTO - NOTNLM
OT  - Antiviral treatment
OT  - HBV-DNA
OT  - hepatocellular carcinoma (HCC)
EDAT- 2017/07/26 06:00
MHDA- 2017/08/05 06:00
CRDT- 2017/07/26 06:00
PHST- 2017/05/19 [received]
PHST- 2017/06/14 [revised]
PHST- 2017/06/16 [accepted]
AID - 37/8/4701 [pii]
PST - ppublish
SO  - Anticancer Res. 2017 Aug;37(8):4701-4706.